Skip to main content

Table 2 Initial treatment, BMMSC treatment, and follow-up

From: Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings

Case Initial treatment MSCS treatment (IT/IA/IV) 3 months (CSF) 6 months (MRI/CSF) 12 months (MRI/CSF) 24 months (MRI/CSF)
1 Prednisone IT+IA Negative MRI negative   
2 Prednisone IT+IA Positive MRI negative
CSF negative
  
3 Prednisone
Cytarabine
IT+IA Negative MRI better
CSF negative
  
4 Prednisone IT+IV after 1 year also IT+IA Negative MRI negative MRI negative
CSF negative
MRI negative
CSF negative
5 Prednisone
Cytarabine
IT+IV Negative MRI better MRI unchanged
CSF negative
MRI unchanged
CSF negative
6 Prednisone, PB, levetiracetam IT+IV Negative MRI unchanged   
7 Prednisone, PB IT+IV Negative MRI negative   
8 Prednisone, PB, levetiracetam, cytarabine IT+IV Negative MRI negative